TY - JOUR
T1 - Statin pharmacogenomics
T2 - Pursuing biomarkers for predicting clinical outcomes
AU - Kitzmiller, Joseph P.
AU - Binkley, Philip F.
AU - Pandey, Saurabh R.
AU - Suhy, Adam M.
AU - Baldassarre, Damiano
AU - Hartmann, Katherine
PY - 2013
Y1 - 2013
N2 - Indicated for treating hyperlipidemias and for the prevention of cardiovascular disease (CVD), statins rank among the most commonly prescribed drug classes. While statins are considered to be highly effective in preventing atherosclerotic events, a substantial portion of treated patients still progress to overt CVD. Genetic factors are thought to contribute substantially to treatment outcome. Several candidate genes have been associated with statin dose requirements and treatment outcomes, but a clinically relevant pharmacogenomics test to guide statin therapy has not yet emerged. Here we define basic pharmacogenomics terminology, present strong candidate genes (CETP, HMGCR, SLCO1B1, ABCB1, and CYP3A4/5), and discuss the challenges in developing much-needed statin pharmacogenomics biomarkers for predicting treatment outcomes.
AB - Indicated for treating hyperlipidemias and for the prevention of cardiovascular disease (CVD), statins rank among the most commonly prescribed drug classes. While statins are considered to be highly effective in preventing atherosclerotic events, a substantial portion of treated patients still progress to overt CVD. Genetic factors are thought to contribute substantially to treatment outcome. Several candidate genes have been associated with statin dose requirements and treatment outcomes, but a clinically relevant pharmacogenomics test to guide statin therapy has not yet emerged. Here we define basic pharmacogenomics terminology, present strong candidate genes (CETP, HMGCR, SLCO1B1, ABCB1, and CYP3A4/5), and discuss the challenges in developing much-needed statin pharmacogenomics biomarkers for predicting treatment outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84886303582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886303582&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84886303582
VL - 16
SP - 45
EP - 51
JO - Discovery medicine
JF - Discovery medicine
SN - 1539-6509
IS - 86
ER -